Screener
Voyager Therapeutics, Inc.
VYGRVoyager Therapeutics is a biotechnology company focused on developing next-generation gene therapies and antibodies for severe neurological diseases.
$187.93M-20.5%
Earnings
Next report
Nov 9, 2026 (in 2 months)Revenue estimate$6.3M
EPS estimate-$0.41
Competitors
By market cap
By revenue growth
Profile
Voyager Therapeutics is a biotechnology company focused on developing next-generation gene therapies and antibodies for severe neurological diseases. The company leverages its proprietary TRACER capsid discovery platform and NeuroShuttle non-viral delivery technology to engineer therapies that can effectively cross the blood-brain barrier via intravenous administration.
Competitive position
A specialized platform player in AAV capsid engineering with a focus on blood-brain barrier penetration for CNS disorders.
GeographiesUnited States, Global
Customer segmentsPharmaceutical companies, Patients
Business modelR&D, Licensing, Collaboration
SuppliersGenetic research data, Contract manufacturing organizations, Laboratory equipment suppliers
CustomersNovartis, Neurocrine Biosciences, AstraZeneca, Specialty pharmacies, Hospitals
CountryUnited States of America
Listed2015
Employees162.0
CEOAlfred W. Sandrock Jr.
SectorHealthcare
IndustryBiotechnology
Websitevoyagertherapeutics.com
FilingsSEC EDGAR
FAQ
- What is Voyager Therapeutics, Inc.'s market cap?
- Voyager Therapeutics, Inc. (VYGR) has a market capitalization of $187.9M and trades on NASDAQ.
- Who are Voyager Therapeutics, Inc.'s competitors?
- Voyager Therapeutics, Inc.'s key competitors include Biogen Inc., Sarepta Therapeutics, Inc., Eli Lilly and Company, and others. These companies compete in similar markets and product categories.
- Who does Voyager Therapeutics, Inc. partner with?
- Voyager Therapeutics, Inc.'s notable partners include Neurocrine Biosciences, Inc., Novartis Pharma AG, Alexion, AstraZeneca Rare Disease, and others.
- Where is Voyager Therapeutics, Inc. headquartered?
- Voyager Therapeutics, Inc. is headquartered in United States of America and employs approximately 162 people. It has been publicly traded since 2015.